Acepodia Enters Strategic Clinical Collaboration with Pfizer to Accelerate Development of Antibody-Cell Conjugation-Based Cell Therapies in Autoimmune Diseases
Rhea-AI Summary
Acepodia (6976:TT) has entered a strategic clinical collaboration with Pfizer Ignite to accelerate the development of its Antibody-Cell Conjugation (ACC) platform for autoimmune diseases. This partnership will provide Acepodia with access to Pfizer's resources, expertise, and strategic guidance throughout the drug development process. Acepodia's ACC platform, based on Nobel laureate Dr. Carolyn Bertozzi's work, offers an off-the-shelf, non-genetically engineered alternative to CAR-T cell therapy with improved scalability and reduced side effects.
The collaboration will also support Acepodia's ongoing clinical programs, including ACE1831 for non-Hodgkin's lymphoma and ACE2016 for solid tumors. ACE1831 has shown promising results in early clinical trials. This partnership aims to address significant unmet needs in autoimmune diseases while leveraging the potential of cell therapies without the limitations of current CAR-T treatments.
Positive
- Strategic collaboration with Pfizer Ignite provides access to valuable resources and expertise
- Expansion of ACC platform application into autoimmune diseases, broadening market potential
- ACE1831 shows robust and durable effect in Phase 1 trial for non-Hodgkin's lymphoma
- ACC platform offers improved scalability and reduced side effects compared to CAR-T therapies
- Acepodia retains all rights related to program progress and future partnership opportunities
Negative
- None.
News Market Reaction – TT
On the day this news was published, TT gained 0.10%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseases
- Pfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 in NHL and ACE2016 in solid tumors
- Acepodia's lead ACC platform therapy has shown clinical benefits in oncology without the limitations of current CAR-T cell therapies
Acepodia's ACC platform, which uses bioorthogonal chemistry and is based on the pioneering work of 2022 Nobel laureate Dr. Carolyn Bertozzi, who applied click chemistry to living systems, creates an off-the-shelf, non-genetically engineered version of CAR-T cell therapy that is more easily scaled and avoids cytokine release storms, neurotoxicity, and other side effects associated with CAR-T cell therapies. Acepodia's lead clinical candidate, ACE1831, is currently being evaluated in a Phase 1 first-in-human clinical trial for patients with non-Hodgkin's lymphoma and has demonstrated a robust and durable effect after a single treatment at the lowest dose.
"The significant unmet needs that exist in autoimmune diseases combined with the early positive results that have been seen with CAR-T therapies have opened the door for potential innovations that could provide the efficacy of CAR-T therapy without the challenges that have made routine use of CAR-T in autoimmune diseases difficult," said Sonny Hsiao, Ph.D., chief executive officer of Acepodia. "We see a significant opportunity to bring the benefits of our ACC platform to autoimmune diseases, and working with Pfizer Ignite will position us well to deliver our immunotherapies to patients in desperate need of new options."
By collaborating with Pfizer Ignite, Acepodia will benefit from Pfizer's resources, deep expertise and R&D capabilities, covering multiple stages such as clinical trial design and regulatory strategies to improve the process of developing innovative drugs.
"Pfizer Ignite is focused on supporting the delivery of innovative therapies that are strategically aligned with Pfizer's priority areas and have the potential to address significant gaps in patient care, " said Kathy Fernando, SVP, Head of Pfizer Ignite. "Drawing on Pfizer's deep expertise in oncology and immunology, we look forward to collaborating with Acepodia to help translate their compelling scientific platform into impactful new medicines for patients with unmet need."
With the agreement, Acepodia will retain all rights related to the progress of the program and future partnership opportunities.
About Acepodia
Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address gaps in cancer care. Leveraging its ACC technology, the company links tumor-targeting antibodies to its proprietary immune cells, such as natural killer and gamma delta T cells, to create novel ACE therapies, which have increased binding strength against tumors that express low levels of tumor antigens.
Acepodia is composed of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable cell therapies to a broad population of patients across a variety of solid tumors and hematologic cancers. For more information, visit www.acepodia.com and follow Acepodia on Twitter and LinkedIn.
View original content:SOURCE Acepodia Inc.
FAQ
What is the purpose of Acepodia's collaboration with Pfizer Ignite?
How does Acepodia's ACC platform differ from traditional CAR-T cell therapies?
What are the current clinical programs of Acepodia (6976:TT)?
Will Acepodia (6976:TT) retain rights to its programs under the Pfizer Ignite collaboration?
